IDXX · Earnings call · 2026Q2T · Full report

Competition and Market Share

IDEXX LABORATORIES INC /DE · 2026-08-04 · Importance 31 · Surprise 32

IDEXX reported global CAG Diagnostics customer retention in the high 90s and an installed base that grew 11% year over year. More than 20% of Cancer Dx orders globally came from practices using a competitive laboratory, contributing to record laboratory conversions and new-customer growth. Management said customers are choosing IDEXX innovations despite existing workflows, while integrated point-of-care, reference-lab, software, and imaging capabilities strengthen the company’s competitive position.

Key facts

• We have seen more assets recently in the software space compared with recent deals we have done in the past.
• Globally, over 20% of Cancer Dx orders come from practices using a competitive lab.
• Customer retention globally remains in the high 90s for CAG Diagnostics business.